Prevail Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Prevail Therapeutics's estimated annual revenue is currently $16.1M per year.
- Prevail Therapeutics's estimated revenue per employee is $155,000
- Prevail Therapeutics's total funding is $129M.
Employee Data
- Prevail Therapeutics has 104 Employees.
- Prevail Therapeutics grew their employee count by 6% last year.
Prevail Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | Associate VP, Preclinical R+D | Reveal Email/Phone |
4 | Associate VP, Scientific Strategy and Communications | Reveal Email/Phone |
5 | Assoc. VP, Genome Engg & Modeling | Reveal Email/Phone |
6 | VP, Clinical Operations | Reveal Email/Phone |
7 | VP, People | Reveal Email/Phone |
8 | VP Global Regulatory Affairs | Reveal Email/Phone |
9 | General Counsel | Reveal Email/Phone |
10 | Executive Director, Global Regulatory Affairs | Reveal Email/Phone |
Prevail Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Prevail Therapeutics?
At Prevail Therapeutics, we are pioneering innovative therapies that aim to cure neurodegenerative disorders, such as Parkinson's disease. Our mission is to translate breakthrough advances in human genetics and gene therapy technology into life-changing medicines that slow, stop and reverse the neurodegenerative process. Our novel gene therapies target patients with urgent unmet needs, where there are currently no available therapies to change the progressive course of their diseases. Prevail was formed in 2017, and as an emerging biotechnology company, we are growing rapidly. We are building a team of dedicated, creative and talented individuals who share our passion for serving patients with neurodegenerative diseases. We pride ourselves on following great science, and we value collaboration, integrity and agility. We are based in the Alexandria Center for Life Science in New York City.
keywords:N/A
$129M
Total Funding
104
Number of Employees
$16.1M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Prevail Therapeutics News
BillionToOne raised $15M; Polyneuron Pharmaceuticals secured $22.6M;Prevail Therapeutics lands $50M Artiphon: Artiphon is empowering a new generation to explore music-making with smart instruments and adaptive software. Artiphon has raised $2 million in seed funding led by Warner Music Group. R ...
Prevail Therapeutics, Inc., a New York, NY-based gene therapy company developing Adeno-Associated Virus-based gene therapies for patients with devastating neurodegenerative diseases, raised $50m in Series B financing. Backers included: – existing investors OrbiMed, Pontifax, RA Capital Managem ...
NEW YORK--(BUSINESS WIRE)--Prevail Therapeutics Inc. (Prevail), a gene therapy company developing AAV-based gene therapies for patients with devastating neurodegenerative diseases, today announced it has raised $50 million in Series B financing. Proceeds of the financing will be used to advance ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $17.7M | 104 | 13% | $23.4M |
#2 | $23.6M | 104 | 8% | N/A |
#3 | $21.8M | 104 | 18% | N/A |
#4 | $14.6M | 104 | -1% | $11.9M |
#5 | $33.6M | 104 | 5% | N/A |